Get access
Clinical & Experimental Allergy

Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine

Authors

  • E. BERCHTOLD,

    1. Allergy Unit and Comprehensive Hospital Drug Monitoring, Medical Division, Zieglerspital, Bern, Switzerland
    Search for more papers by this author
  • R. MAIBACH,

    1. Allergy Unit and Comprehensive Hospital Drug Monitoring, Medical Division, Zieglerspital, Bern, Switzerland
    Search for more papers by this author
  • U. MÜLLER

    Corresponding author
    1. Allergy Unit and Comprehensive Hospital Drug Monitoring, Medical Division, Zieglerspital, Bern, Switzerland
      Dr U. Müller, Medizinische Klinik, Zieglerspital, CH-3007 Bern, Switzerland.
    Search for more papers by this author

Dr U. Müller, Medizinische Klinik, Zieglerspital, CH-3007 Bern, Switzerland.

Summary

In a double-blind placebo-controlled trial on 52 patients with bee venom allergy we studied the effect of a pretreatment with terfenadine 120 mg twice daily on the occurrence of local and systemic allergic side effects from rush-immunotherapy. Large local reactions were significantly reduced by terfenadine pretreatment (P < 0.01), while systemic side effects were observed with similar frequencies in both groups. Analysis of individual systemic allergic manifestations showed that cutaneous symptoms like itching (P < 0.025) and urticaria/angioedema (P < 0.05) were significantly reduced, while respiratory or cardiovascular symptoms were not influenced. A lower consumption of additional anti-allergic medication was found during terfenadine pretreatment (p < 0.05). Pretreatment with antihistamines during immunotherapy may thus be helpful in the management of patients with cutaneous side effects.

Get access to the full text of this article

Ancillary